E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers P > Headlines for Prestwick Pharmaceuticals, Inc. > News item
Published on 12/20/2005 in the Prospect News Biotech Daily.

Prestwick Pharmaceuticals cancels IPO

By Ted A. Knutson

Washington, Dec. 20 - Prestwick Pharmaceuticals, Inc. canceled its planned $74.75 million initial public offering of common stock due to market conditions, according to a registration RW filing with the Securities and Exchange Commission.

UBS Investment Bank, Deutsche Bank Securities and CIBC World Markets were to have been the underwriters.

Washington, D.C.-based Prestwick focuses on developing small molecule drugs for the central nervous system.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.